Compare JRVR & TKNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JRVR | TKNO |
|---|---|---|
| Founded | 2002 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.7M | 236.6M |
| IPO Year | 2005 | 2021 |
| Metric | JRVR | TKNO |
|---|---|---|
| Price | $6.25 | $3.88 |
| Analyst Decision | Hold | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $6.25 | N/A |
| AVG Volume (30 Days) | ★ 281.8K | 128.5K |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | ★ 0.63% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $646,580,000.00 | $39,801,000.00 |
| Revenue This Year | N/A | $8.79 |
| Revenue Next Year | $0.17 | $10.52 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 9.50 |
| 52 Week Low | $3.00 | $3.85 |
| 52 Week High | $6.89 | $10.37 |
| Indicator | JRVR | TKNO |
|---|---|---|
| Relative Strength Index (RSI) | 52.02 | 30.91 |
| Support Level | $6.26 | $3.85 |
| Resistance Level | $6.48 | $4.86 |
| Average True Range (ATR) | 0.23 | 0.29 |
| MACD | -0.05 | -0.07 |
| Stochastic Oscillator | 35.00 | 14.17 |
James River Group Holdings Ltd owns and operates a group of specialty insurance and reinsurance companies. It reports business into three segments. The Excess and Surplus Lines segment, which is the key revenue driver, offers commercial excess and surplus lines liability and excess property insurance products; The Specialty Admitted Insurance segment focuses on niche classes within the standard insurance markets with a primary focus on fronting business, where it retains a minority share of the risk and seek to earn fee income by allowing other carriers and producers to use its licensure, ratings, expertise and infrastructure, and the Corporate and other segment consists of the management and treasury activities of holding companies, and equity compensation for the group.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.